Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: An update on the recent patent literature

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 4, 2014, Pages 383-400

  Lavecchia, Antonio ^a   Di Giovanni, Carmen ^a   Cerchia, Carmen ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anticancer drugs; Cancer therapeutics; JAK STAT pathway; Molecular therapeutics; Oncogene; Protein protein interactions; STAT3 inhibitors

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; ANTHRAQUINONE DERIVATIVE; EP 2504000 A1; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 20110172429; US 20110201565; US 20110212911; US 20120130079; US 20120302524; US 20120322807; WO 2006091837; WO 2009042677; WO 2011055320; WO 2011069141; WO 2011081205; WO 2011084694; WO 2011163424; WO 2012/078982; WO 2012010555; WO 2012018868; WO 2012097351; WO 2012142615; WO 2013063504; WP 1066; WP 1193; WP 1220; OLIGONUCLEOTIDE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DIMERIZATION; HUMAN; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR PORE COMPLEX; PATENT; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; NEOPLASMS; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

ANIMALS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; OLIGONUCLEOTIDES; PATENTS AS TOPIC; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84896471189     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.877443     Document Type: Review

References (87)

1. Bromberg J. STAT proteins and oncogenesis. J Clin Invest 2002;109:1139-42
2. Siddiquee KA, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67
3. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-88
4. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105
5. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26
6. Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011;18:2359-75
7. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21
8. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune esponses by STAT-3 signaling in tumor cells. Nat Med 2004;10:48-54
9. Becker S, Groner B, Müller CW. Three-dimensional structure of the STAT3beta homodimer bound to DNA. Nature 1998;394:145-51
10. Ren Z, Mao X, Mertens C, et al. Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun 2008;374:1-5
11. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12
12. Wakahara R, Kunimoto H, Tanino K. Phospho-Ser727 of STAT3 regulates STAT3 activity byenhancing dephosphorylation of phospho-Tyr705 largely through TC45. Genes Cells 2012;17:132-45
13. Liddle FJ, Alvarez JA, Poli V, et al. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 2006;45:5599-605
14. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5
15. Yokogami K, Wakisaka S, Avruch J, et al. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000;10:47-50
16. Yuan ZL, Guan YJ, Chatterjee D, et al. STAT3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-73
17. Herrmann A, Vogt M, Monnigmann M, et al. Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci 2007;120:3249-61
18. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12
19. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005;102:8150-5
20. Ma J, Cao X. Regulation of STAT3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal 2006;18:1117-26
21. Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Patents 2011;21:65-83
22. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276:45443-55
23. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013;12:611-29
24. Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009;87:825-33
25. Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102:4700-5
26. Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. Mol Cancer 2007;7:111
27. Farjo RA. STAT3 inhibiting compositions and methods. WO042677; 2009
28. Charlesson Llc. STAT3 inhibiting compositions and methods. US0077306; 2011
29. Suganami E, Takagi H, Ohashi H. Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004;53:2443-8
30. Toronto Mississauga Univ, Central Florida Res Found Univ. Compounds that suppress cancer cells and exhibit antitumor activity. US0130079; 2012
31. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104:7391-6
32. Fletcher S, Singh J, Zhang X, et al. Disruption of transcriptionally active STAT3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. ChemBioChem 2009;10:1959-64
33. Central Florida Res Found Univ, Toronto Mississauga Univ. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of STAT3. WO163424; 2011
34. Central Florida Res Found Univ, Toronto Mississauga Univ. Substituted 2-hydroxy-4-(2-(phenylsulfonamido) acetamido)benzoic acid analogs as inhibitors of STAT proteins. WO018868; 2012
35. Gen, Inc. Ass Pharma Valley Project Supporting Organisation, Kabushiki Kaisha Yakult, Kumamoto Health Science Univ., et al. 1, 3, 4-oxadiazole-2- carboxamide compound. EP2520575; 2012
36. Pharma Ip General, Inc. Ass, Pharma Design, Inc., Shizuoka Prefecture, et al. 1, 3, 4-oxadiazole-2-carboxamide compound. WO081205; 2011
37. Gen, Inc. Ass Pharma Valley Project Supporting Organisation, Pharma Design, Inc., Kabushiki Kaisha Yakult Honsha, et al. 1, 3, 4-oxadiazole-2- carboxamide compound. US0302524; 2012
38. Pharma Ip General, Inc. Ass, Pharma Design, Inc., Shizouka Prefecture, et al. STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient. US0172429; 2011
39. Piramal Life Sciences Ltd. Imidazopyridine derivatives. WO055320; 2011
40. Lin L, Hutzen B, Li PK, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010;12:39-50
41. Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. WO066263; 2011
42. Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. US0212911; 2011
43. Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. EP2504000A1; 2012
44. Nationwide Children's Hospital, Inc., Ohio State Univ. Materials and methods to inhibit multiple myeloma cancer cells. WO097351; 2012
45. Texas System Univ. Interferon therapies in combination with blockade of STAT3 activation. WO069141; 2011
46. Texas System Univ. Interferon therapies in combination with blockade of STAT3 activation. US129675; 2013
47. Texas System Univ. Compounds for treatment of cell proliferative diseases. WO058829; 2005
48. Texas System Univ. Orally bioavailable caffeic acid related anticancer drugs. WO115269; 2007
49. Texas System Univ. Orally bioavailable caffeic acid related anticancer drugs. US232668; 2007
50. Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Patents CNS Drug Discov 2008;3:179-88
51. Morford LA, Elliott LH, Carlson SL, et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 1997;159:4415-25
52. Kong LY, Abou-Ghazal MK, Wei J, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008;14:5759-68
53. Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67:11291-9
54. Horiguchi A, Asano T, Kuroda K, et al. WP1066, STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9
55. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44
56. South Florida Univ. Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism. US201565; 2011
57. Parker-Athill E, Luo D, Bailey A, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009;217:20-7
58. Weidler M, Rether J, Anke T, et al. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett 2000;484:1-6
59. Partners F€or Utvecklingsinvesteringar Inom Life Sciences PULS Ab. Tricyclic lactones for treatment of cancer. WO010555; 2012
60. Ohio State Univ, Nationwide Children S Hospital, Inc., Miami Univ. XZH-5 inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human hepatocellular carcinoma cells. WO078982; 2012
61. Liu A, Liu Y, Jin Z, et al. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One 2012;7:e46624
62. Liu Y, Liu A, Xu Z, et al. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis 2011;16:502-10
63. Otsuka Pharma Co. Ltd. STAT3/5 activation inhibitor. US322807; 2012
64. Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009;63:983-95
65. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;7:4138-43
66. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;6:970-9
67. Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149
68. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513
69. Chan KS, Sano S, Kiguchi K, et al. Disruption of STAT3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8
70. Shen J, Li R, Li G. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In vivo 2009;23:237-43
71. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2012;8:694-705
72. Pittsburgh Univ. Mellon C. Stabilized STAT3 decoy oligonucleotides and uses therefor. WO084694; 2011
73. Pittsburgh Univ. Mellon C. Stabilized STAT3 decoy oligonucleotides and uses therefor. US288536; 2012
74. Grandis JR, Johnson DE, Leong P, et al. STAT3 decoy oligonucleotides and uses therefor. WO012625; 2006
75. Houssier C, Depauw-Gillet MC, Hacha R, et al. Alteration in the nucleosome and chromatin structures upon interaction with platinum coordination complexes. Biochim Biophys Acta 1983;3:317-25
76. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;38:32979-88
77. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;12:1533-42
78. H. Lee Moffitt Cancer Cent and Res. Inst. Central Florida Res. Found Univ. Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells. WO063504; 2013
79. Texas System Univ. Auranofin and auranofin analogs useful to treat proliferative disease and disorders. WO142615; 2012
80. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22
81. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56
82. Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011;17:3922-32
83. Wu WY, Li J, Wu ZS, et al. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506
84. Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9
85. Kim MJ, Nam HJ, Kim HP, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013;335:145-52
86. Hintersteiner M, Ambrus G, Bednenko J. Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. ACS Chem Biol 2010;5:967-79
87. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005;102:8150-5